FDA Okays Empagliflozin for HF Regardless of Ejection Fraction FDA Okays Empagliflozin for HF Regardless of Ejection Fraction
The expanded indication for the SGLT2 inhibitor empagliflozin (Jardiance) now includes heart failure with mid-range or preserved left-ventricular ejection fraction — essentially all heart failure.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 24, 2022 Category: Cardiology Tags: Cardiology News Alert Source Type: news
FDA approves treatment for wider range of patients with heart failure
Today, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control in adults with type 2 diabetes. (Source: World Pharma News)
Source: World Pharma News - February 24, 2022 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Semaglutide + metformin not cost effective vs empagliflozin + metformin for T2DM in Denmark
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2021 Category: Drugs & Pharmacology Source Type: news
Boehringer Ingelheim's diabetes pill Jardiance gets CDSCO nod for use against heart failure
German drug maker Boehringer Ingelheim has won approval from the Indian drug regulator to market its top-selling type-2 diabetes medication Jardiance (empagliflozin) in India, for additional indication to reduce the risk of heart failure in adults. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 22, 2021 Category: Pharmaceuticals Source Type: news
Empagliflozin Wins in Tough Stabilized Acute-HF Setting Empagliflozin Wins in Tough Stabilized Acute-HF Setting
Early in-hospital initiation of SGLT2 inhibitors ' should be considered the new standard of care ' in most patients with heart failure regardless of their ejection fraction, says an expert observer.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 16, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Advanced CKD Doesn't Derail Empagliflozin in EMPEROR-Preserved Advanced CKD Doesn't Derail Empagliflozin in EMPEROR-Preserved
A prespecified data analysis from EMPEROR-Preserved in patients with HFpEF showed consistent efficacy and safety results for empagliflozin regardless of chronic kidney disease status.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 12, 2021 Category: Cardiology Tags: Pathology & Lab Medicine News Source Type: news
emperor-preserved-kidney-subanalysis
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease statusIn a new sub-analysis of the landmark EMPEROR-Preserved ®Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline1 Empagliflozin consistently improved outcomes across the full range of kidney function down to an eGFR of 20 mL/min/1.73 m21 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2021 Category: Research Source Type: news
Empagliflozin less costly than other branded AHAs for T2DM patients with CVD in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Boehringer Ingelheim gets interim injunction against Dr. Reddy ’s Labs, MSN Labs against copies of anti-diabetes drug
In a statement to ET, BI confirmed it has obtained separate orders granting ad-interim injunction that restrains the two domestic pharmaceutical manufacturers from launching, making, using, offering for sale, selling, importing and/or exporting their respective generic version of empagliflozin drugs. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 26, 2021 Category: Pharmaceuticals Source Type: news
MSN Labs launches patented diabetes pill Jardiance after DRL, heats up potential legal battle
Earlier, ET reported that Dr Reddy's Labs has launched copies of Jardiance. It has a valid patent in India until 2025. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2021 Category: Pharmaceuticals Source Type: news
Empagliflozin's HFpEF Efficacy Catalyzes Redefinition of HF Empagliflozin's HFpEF Efficacy Catalyzes Redefinition of HF
Groundbreaking results from the EMPEROR-Preserved trial have helped catalyze a paradigm shift in how thought leaders view ejection fraction in making important distinctions among HF patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
Empagliflozin Benefits Tied to Drop in NT-proBNP Levels in Patients With Heart Failure Empagliflozin Benefits Tied to Drop in NT-proBNP Levels in Patients With Heart Failure
Empagliflozin reduced the risk of adverse cardiovascular and renal outcomes in heart failure patients regardless of baseline NT-proBNP levels, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)Breakthrough Designation awarded following empagliflozin ’s results in first and only successful trial for HFpEF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news
Empagliflozin Win in EMPEROR-Preserved HF, but Renal Outcomes Puzzle Empagliflozin Win in EMPEROR-Preserved HF, but Renal Outcomes Puzzle
The EMPEROR-Preserved trial of empagliflozin to treat patients with HFpEF comes with a lot more outcome analyses that also deserve attention, most notably some puzzling renal findings.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context
Javed Butler discusses the details of the trial on empagliflozin in HFpEF with Ileana Pi ña and what might be learned from the subgroup analyses.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 31, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news
